Understanding & Targeting Renal Fibrosis to Advance Antifibrotic Innovation
- Explore the key signalling pathways and cellular players including myofibroblasts, epithelial cells, macrophages driving CKD progression and fibrogenesis
- Explore omics-driven insights into spatial and cellular heterogeneity within nephron structures to inform more precise therapeutic approaches
- Examine the promise of ROCK2 inhibition, including preclinical and early clinical findings from GRV-101, and how biomarker-driven strategies are guiding antifibrotic drug development in renal disease